


In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2005/000832.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (original). A compound of general formula (I):



wherein X_1 is H or COR_1 and X_2 is H or COR_2 but X_1 and X_2 are not both H;

R_1 and R_2 are the same or different and are each C_{1-4} alkyl substituted with R_3 , or a four to seven-membered ring which can be optionally substituted with R_8 and can contain one or more additional heteroatoms selected from O, $S(O)_n$ and NR_9 ;

R_3 is F, CF_3 , OR_4 , NR_5R_6 or $S(O)_nR_7$;

R_4 , R_5 , and R_6 are the same or different and are each H or C_{1-4} alkyl optionally substituted with R_3 , or NR_5R_6 is a C_{4-6} heterocycloalkyl ring containing one or more heteroatoms selected from O, NR_8 and $S(O)_n$;

each n is 0-2;

R_7 is C_{1-4} alkyl;

R_8 is as defined for R_3 or C_{1-4} alkyl optionally substituted with R_3 or halogen;

and

R_9 is H or C_{1-4} alkyl;

or a salt, solvate or hydrate thereof.

2 (currently amended). [[A]] The compound of claim 1, wherein X_1 is COR_1 and X_2 is COR_2 .

3 (currently amended). [[A]] The compound of claim 1, wherein X_1 is H and X_2 is COR_2 .


4 (currently amended). [[A]] The compound of claim 1, wherein X_1 is COR_1 and X_2 is H.

5 (currently amended). [[A]] The compound of ~~any preceding claim 1~~, wherein R_3 is CF_3 , OR_4 , NR_5R_6 or $S(O)_nR_7$.

6 (currently amended. [[A]] The compound of claim 1, which is 4,5-Bis(tetrahydropyran-4-carbonloxy)-9,10-dioxo-dihydroanthracene-2-carboxylic acid.

7 (currently amended). [[A]] The compound of claim 1, which is;
 4,5-bisbutyryloxy-9, 10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
 4,5-bis(2-benzyloxyacetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
 4,5-bis(4-methoxybutyryloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
 or
 4,5-bis(tetrahydrofuran-3-carbonyloxy)-9, 10-dioxo-9,10-dihydroanthracene-2-carboxylic acid.

8 (currently amended). A pharmaceutical composition for use in therapy, comprising ~~a compound of any of claims 1 to 7~~ and a pharmaceutically acceptable diluent or carrier and a compound of general formula (I):



wherein X_1 is H or COR_1 and X_2 is H or COR_2 but X_1 and X_2 are not both H;

R_1 and R_2 are the same or different and are each C_{1-4} alkyl substituted with R_3 , or a four to seven-membered ring which can be optionally substituted with R_8 and can contain one or more additional heteroatoms selected from O, $S(O)_n$ and NR_9 ;

R_3 is F, CF_3 , OR_4 , NR_5R_6 or $S(O)_nR_7$;

R_4 , R_5 , and R_6 are the same or different and are each H or C_{1-4} alkyl optionally substituted with R_3 , or NR_5R_6 is a C_{4-6} heterocycloalkyl ring containing one or more heteroatoms selected from O, NR_8 and $S(O)_n$;

each n is 0-2;

R_7 is C_{1-4} alkyl;


R_8 is as defined for R_3 or C_{1-4} alkyl optionally substituted with R_3 or halogen;

and

R_9 is H or C_{1-4} alkyl;

or a salt, solvate or hydrate thereof.

9 (currently amended). ~~Use of a compound of any of claims 1 to 7, for the manufacture of a medicament~~ A method for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines wherein said method comprises administering, to a patient in need of such treatment, a compound of general formula (I):



wherein X_1 is H or COR_1 and X_2 is H or COR_2 but X_1 and X_2 are not both H;

R_1 and R_2 are the same or different and are each C_{1-4} alkyl substituted with R_3 , or a four to seven-membered ring which can be optionally substituted with R_8 and can contain one or more additional heteroatoms selected from O, $S(O)_n$ and NR_9 ;

R₃ is F, CF₃, OR₄, NR₅R₆ or S(O)_nR₇;

R₄, R₅, and R₆ are the same or different and are each H or C₁₋₄ alkyl optionally substituted with R₃, or NR₅R₆ is a C₄₋₆ heterocycloalkyl ring containing one or more heteroatoms selected from O, NR₈ and S(O)_n;

each n is 0-2;

R₇ is C₁₋₄ alkyl;

R₈ is as defined for R₃ or C₁₋₄ alkyl optionally substituted with R₃ or halogen;

and

R₉ is H or C₁₋₄ alkyl;

or a salt, solvate or hydrate thereof.

10 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a chronic degenerative disease ~~such as rheumatoid arthritis, osteoarthritis or osteoporosis.~~

11 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a chronic demyelinating disease ~~such as multiple sclerosis.~~

12 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a respiratory disease ~~such as asthma or chronic obstructive pulmonary disease (COPD).~~

13 (currently amended). [[Use]] The method according to claim 9, wherein the condition is an inflammatory bowel disease (IBD) ~~such as ulcerative colitis or Crohn's disease.~~

14 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a dermatological condition ~~such as psoriasis, scleroderma or atopic dermatitis.~~

15 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a dental disease ~~such as periodontal disease or gingivitis.~~

16 (currently amended). [[Use]] The method according to claim 9, wherein the condition is a diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis.

17 (currently amended). [[Use]] The method according to claim 9, wherein the condition is systemic lupus erythematosus (SLE).

18 (currently amended). [[Use]] The method according to claim 9, wherein the condition is graft vs host disease.

19 (new). The method, according to claim 10, wherein said condition is rheumatoid arthritis, osteoarthritis or osteoporosis

20 (new). The method, according to claim 11, wherein said condition is multiple sclerosis.

21 (new). The method, according to claim 12, wherein said condition is asthma or chronic obstructive pulmonary disease (COPD).

22 (new). The method, according to claim 13, wherein said condition is ulcerative colitis or Crohn's disease.

23 (new). The method according to claim 14, wherein said condition is scleroderma or atopic dermatitis

24 (new). The method according to claim 15, wherein said condition is periodontal disease or gingivitis